OpenAI Researcher Miles Wang to Leave for Startup, New Team Plans to Develop AI Models for Drug Discovery
TechCrunch cites sources that OpenAI researcher Miles Wang will leave to start a new venture. He previously researched AI to accelerate scientific and biological discoveries. The new team plans to develop AI models for drug discovery, with several OpenAI researchers likely to join. The team is negotiating about $200 million in funding, with a valuation of around $2 billion, and Lightspeed may lead the investment, focusing on finding new uses for existing drugs. Market mechanisms indicate that talent outflow and new project financing are driving capital towards the intersection of AI and biomedicine, with institutions increasing stakes in AI drug discovery startups, as funds shift from general large models to vertical applications, benefiting from VCs like Lightspeed and potential pharmaceutical partners. Source: Public Information
ABAB AI Insight
OpenAI has previously faced multiple rounds of talent loss, with researchers leaving to start competing projects, similar to the early entrepreneurial wave of DeepMind scientists. In terms of capital pathways, the new team aims to accelerate the development of AI drug discovery models through $200 million in funding, focusing resources on new uses for existing drugs and biological breakthroughs, motivated by capturing commercialization opportunities in AI as a scientific accelerator. Similar to AI drug platforms like Insilico Medicine or Exscientia, the current AI biomedicine field is in the early stages of transitioning from research tools to clinical applications. Essentially, this represents a technological substitution change, with OpenAI's talent outflow accelerating the vertical penetration of AI into drug discovery, driven by the rapid migration of large model capabilities into high-value biological fields, promoting the concentration of capital and talent towards cross-innovation and achieving a structural leap in pharmaceutical research and development efficiency. ABAB News · Cognitive Law 1. Talent outflow accelerates vertical AI applications. 2. New uses for existing drugs reduce drug discovery costs. 3. AI-biomedical intersection reshapes pharmaceutical capital pathways.